Skip to Content

UK Edition. Click here for US version.


PDF options:  View Fullscreen   Download PDF

PDF Transcript


Novgos 3.6 mg Implant

Read all of this leaflet carefully before you start using this medicine.
• Keep this leaflet. You may need to read it again.
• If you have any further questions, ask your doctor.
• This medicine has been prescribed for you. Do not pass it on to others. It may harm them, even if
their symptoms are the same as yours.
• If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet,
please tell your doctor.
In this leaflet:
1. What Novgos is and what it is used for
2. Before you use Novgos
3. How to use Novgos
4. Possible side effects
5. How to store Novgos
6. Further information



Novgos is a medicine that acts like a hormone. It belongs to a group of medicines called LHRH
agonists. It reduces the production of the male sexual hormone (testosterone) or the female sexual
hormone (oestrogen) in the body.
Novgos is used in men to treat prostate cancer.



Do not use Novgos
• if you are allergic to goserelin or any of the other ingredients of Novgos.
• in children.
Take special care with Novgos
• if you have or have had problems passing urine or if you have or have had problems with your
back. Please, tell your doctor if so.
Previous treatment
• if you had a previous treatment with another medicine in this group because they can cause a small
loss of calcium from the bones (thinning of bones). Some recovery of this loss can occur when
treatment is stopped. If you are suffering from any disease which affects the strength of your bones
please make sure that your doctor is aware of this.
• Novgos must not be used in children.

Using other medicines

Please tell your doctor if you are taking or have recently taken any other medicines, including
medicines obtained without prescription.
Driving and using machines
We do not know whether Novgos could affect your ability to drive a car or operate machines.



The implant is given as an injection under the skin on your stomach by your doctor.
Novgos should be given every month (four weeks). Always remind your doctor or nurse to set up an
appointment for your next injection.
This dosage is the same for patients with impaired kidney or liver function and for elderly patients.
If you think that the symptoms have changed or worsened, please ask your doctor. He will be able to
decide if any changes are needed to your treatment.
If you use more Novgos than you should
If you receive an injection too early (less than four weeks after the previous injection) please inform
your doctor.
If you forget to use Novgos
Please talk to your doctor if you think the 4-weekly use of Novgos has been forgotten.
If you stop using Novgos
Generally the treatment with Novgos is a long-term treatment.
It is important that you keep on receiving your treatment, even if you are feeling well, unless your
doctor decides that it is time to stop the treatment.
If you have further questions regarding the use of this medicine, please ask your doctor or pharmacist.



Like all medicines, Novgos can cause side effects, although not everybody gets them.
Frequencies of side effects are defined as:
Very common: more than 1 in 10 treated patients
more than 1 in 100 less than 1 in 10 treated patients
Uncommon: more than 1 in 1000 treated patients less than 1 in 100 treated patients
more than 1 in 10,000 treated patients less than 1 in 1000 treated patients
Very rare:
1 or less in 10,000 treated patients including isolated reports
Cardiac disorders:
too low or too high blood pressure
Nervous system disorders:
Very common: tingling in fingers or toes
Very rare:
severe headaches, sickness, loss of eyesight or unconsciousness caused if there is
tumour in the pituitary gland that bleeds or collapses
Skin and subcutaneous tissue disorders:
mild skin rash

Musculoskeletal and connective tissue disorders:
Very rare:
pain in the joints
General disorders and administration site conditions:
local reactions at the injection site
Immune system disorders:
allergic reactions, including the symptoms of an immediate allergy

At the beginning of the treatment certain symptoms may occur:
Nervous system disorders:
Very rare:
lower back pain
Renal and urinary disorders:
Very rare:
problems with passing urine
Musculoskeletal and connective tissue disorders:
bone pain

During treatment the following symptoms may occur:
Nervous system disorders:
Very rare:
benign tumors of the pituitary gland
Endocrine disorders:
Very common: hot flushes and sweating
Reproductive system and breast disorders:
Very common: reduced sex drive, reduction in the size of the testicles
breast swelling
Very rare:
breast tenderness
Treatment with Novgos may affect the strength of your bones. Therefore you may have a higher risk
of suffering from bone fractures than usual.
If any of the side effects get serious, or if you notice any side effects not listed in this leaflet, please
tell your doctor or pharmacist.



Keep out of reach and sight of children.
Novgos should not be used after EXP which is stated on the pouches and the carton. The expiry date
refers to the last day of that month.
Do not store above 25° C. Store in the original package.
Do not use the implant or applicator if you notice that the packaging is damaged.
After opening the pouch the product should be used immediately.


Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to
dispose of medicines no longer required. These measures will help to protect the environment.



What Novgos contains
The active substance is goserelin.
1 Implant contains 3.6 mg goserelin (as goserelin acetate).
The other ingredient is Poly(D,L-lactide-co-glycolide).
What Novgos looks like and contents of the pack
Novgos is a sterile, cylindrical, white to cream cloured implant placed in a sterile injection needle.
The package contains:
One pouch including one sterile injection needle and a desiccant.
One pouch including one sterile applicator.
Novgos is available in packs of 1, 3 and 6 implants.
Not all pack sizes may be marketed.
Marketing authorisation holder and manufacturer
Acino AG
Am Windfeld 35
D-83714 Miesbach

This medicinal product is authorised in the Member States of the EEA under the following
Novogos 3,6 mg Implantat
Goserelin cell pharm 3,6 mg Implantat
KISLIAR 3,6 mg Impianto
Novgos 3,6 mg Implante
United Kingdom:
Novgos 3.6 mg Implant

This leaflet was last approved in January 2013
Notes for the doctor:
Novgos consists of two pouches, the sterile injection needle and the sterile applicator. Note that the
implant is visibly fixed in the injection needle. Open both pouches and connect the injection needle
to the applicator via the Luer lock. Make sure that the connection is tight and that the plunger
remains unchanged in its position.
Check that the implant is visible in the control window in the needle.
Remove the locking device from the plunger. Insert the cannula into the anterior abdominal wall
and insert the implant by depressing the plunger completely.
In addition please pay attention to the detailed application advice on the outer pack.


+ Expand Transcript

Source: Medicines and Healthcare Products Regulatory Agency

Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.